Whatever people may think of the value of "slow and steady" in biotech/equities/investing, I wonder how you square these sentiments with Berger's decisions to:
(1) push Iclusig at 45mg when even knowledgeable message board folks thought the dose was too aggressive,
(2) thumb his nose at the FDA, igniting a pissing contest that got Iclusig yanked from the market,
(3) push briga to a dose level that killed a patient in an ill-conceived effort to get a two-for with EGFR, or
(4) build a giant, two-continent sales force for a drug that had a last-line safety profile?
Maybe Berger gets "slow" in my book, but not in the same way....
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.